Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Earlier this year, the NEJM published interim data on atacicept and sibeprenlimab in IgAN, both well-designed Phase 3 pivotal registration trials of promising drugs [1],[2]. Sponsors were clearly anxious to show the world how well their drug is working, but why publish interim results? After all, IA data are usually Continue reading IgAN Therapy – It’s Getting Crowded Out There
In a recent blog we took issue with a Nature article about ‘Lessons learned’ after a TIGIT inhibitor failed in late Phase 3 development. We felt that the article provided few insights, mainly platitudes. This week we saw a different kind of post-mortem. It was about VRG50635, a PIKfyve inhibitor Continue reading VRG50635 – Lessons Learned in ALS
There was not much for us to report on this summer that would interest our readership… Let’s skip the Fauci / Paul senate drama regarding the origins of Covid, with senator Paul taking the role of the Grand Inquisitor and Dr. Fauci the Fifth. The latest act in this screen Continue reading Avacopan / TAVNEOS Follow-Up